S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
The Next Big Crisis Is Here (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
The Next Big Crisis Is Here (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
The Next Big Crisis Is Here (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
The Next Big Crisis Is Here (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
The Next Big Crisis Is Here (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
The Next Big Crisis Is Here (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
Is This The End of Capitalism? (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
The Next Big Crisis Is Here (Ad)
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Grab Shares Are Suddenly On Track To Double
The Next Big Crisis Is Here (Ad)
Buying The Dip In Colgate-Palmolive 
GE Healthcare Technology: Speculating On Dividends 
OTCMKTS:CLIGF

Clinigen Group - CLIGF Stock Forecast, Price & News

$8.02
0.00 (0.00%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.02
$8.02
50-Day Range
$8.02
$8.02
52-Week Range
$8.02
$11.56
Volume
N/A
Average Volume
8,620 shs
Market Capitalization
$981.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CLIGF stock logo

About Clinigen Group (OTCMKTS:CLIGF) Stock

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Receive CLIGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter.

CLIGF Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Form 8.5 (EPT/NON-RI) - Clinigen Group plc - Amendment
Octopus Investments : Form 8.3 - Octopus Investments Clinigen Group plc
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
BlackRock Group : Form 8.3 - Clinigen Group plc
FORM 8.3 – CLINIGEN GROUP PLC
Clinigen Group plc : Annual Financial Report
Clinigen Group plc : Clinigen signs agreement with ORPHELIA Pharma
Clinigen Group plc : Year End Trading Update
What Does Clinigen Group's (LON:CLIN) CEO Pay Reveal?
Clinigen Group plc (CLIGF)
See More Headlines
Receive CLIGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter.

CLIGF Company Calendar

Today
1/31/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CLIGF
Previous Symbol
NASDAQ:CLIGF
CIK
N/A
Employees
1,069
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$704.71 million
Cash Flow
$1.43 per share
Book Value
$4.52 per share

Miscellaneous

Free Float
N/A
Market Cap
$981.12 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Mr. Shaun Edward Chilton (Age 54)
    CEO & Exec. Director
    Comp: $867.89k
  • Richard Paling
    Interim Chief Financial Officer & Group Financial Controller
  • Mr. Sam Herbert
    Chief Operating Officer
  • Rob Fox
    VP of Investor Relations & Corp. Devel.
  • Ms. Amanda Miller
    Gen. Counsel & Company Sec.
  • Mr. David Bryant
    Director of Corp. Devel.
  • Jessica Archer
    Global HR Director
  • Mr. Mark Corbett
    Managing Director of Global Access Division
  • Mr. Johannes Willemse (Age 54)
    Chief Commercial Officer
  • Mr. Ivo Timmermans M.D. (Age 62)
    MBA, Chief Medial Officer













CLIGF Stock - Frequently Asked Questions

How have CLIGF shares performed in 2023?

Clinigen Group's stock was trading at $8.0157 at the beginning of 2023. Since then, CLIGF shares have increased by 0.0% and is now trading at $8.0157.
View the best growth stocks for 2023 here
.

What is Clinigen Group's stock symbol?

Clinigen Group trades on the OTCMKTS under the ticker symbol "CLIGF."

How do I buy shares of Clinigen Group?

Shares of CLIGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clinigen Group's stock price today?

One share of CLIGF stock can currently be purchased for approximately $8.02.

How much money does Clinigen Group make?

Clinigen Group (OTCMKTS:CLIGF) has a market capitalization of $1.07 billion and generates $704.71 million in revenue each year.

How many employees does Clinigen Group have?

The company employs 1,069 workers across the globe.

How can I contact Clinigen Group?

Clinigen Group's mailing address is PITCAIRN HOUSE CROWN SQUARE FIRST AVENUE, Burton-on-Trent X0, DE14 2WW. The official website for the company is www.clinigengroup.com. The company can be reached via phone at 44-12-8349-5010 or via fax at 01283 495011.

This page (OTCMKTS:CLIGF) was last updated on 1/31/2023 by MarketBeat.com Staff